A practical reference on GHRH receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-14 and is reviewed periodically as new material appears.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
=== Business === Morea has been involved in multiple entrepreneurial initiatives. In 2012, he co-founded the merchandising company Cool Maal with cricketer MS Dhoni and Yuvraj Singh. He later established Clockwise Films, a production company, in 2013. That same year, he co-founded a lifestyle and entertainment venture called Playground with Nandita Mahtani. He has partnership with a photo sharing app called Vebbler. He owns a restaurants named Crepe Station Café in Bandra. It is one of the fastest developing chains in India which offers pancakes, waffles and eggs benedict. In 2013, he initiated the installation of outdoor fitness stations in Wadala and Bandra, Mumbai. These facilities were inaugurated with the involvement of actor Hrithik Roshan and politician Aaditya Thackeray. In 2019, Morea and restaurateur Ketan Kadam received an award from People for the Ethical Treatment of Animals (PETA) for a project aimed at replacing horse-drawn carriages in Mumbai with battery-operated electric vehicles. He is also the co-founder of The Fresh Press, a cold-pressed juice brand, and serves as a board director at the Gruhas Collective Consumer Fund (GCCF), an investment platform focused on consumer brands.
=== Part Two === The Purchase Brothers had initially planned to release the second part of the film in early to mid-March 2009, but the large number of emails and phone calls the two received regarding the first part slowed development of the second. According to teaser clips at the end of the first part, the two Resistance soldiers will be joined by two additional characters, one of them a heroine, and will come into contact with headcrab zombies. The Purchase Brothers cited on their YouTube profile page that a new secret film project has heavily hampered their progress in completing Part Two, although it would be released in the near future. Another teaser clip was released on YouTube on October 13, 2009. Part Two was released on YouTube on August 19, 2011. The clip was quickly removed for unknown reasons by the end of the same day with no further comment on why it was removed. It was re-uploaded on August 24, 2011.
They can be synthesized/released and broken down again in specific reactions by enzymes or ion channels. Some (such as Ca2+) can be stored in special organelles and quickly released when needed. Their production/release and destruction can be localized, enabling the cell to limit space and time of signal activity.
Sources: en.wikipedia.org
== Experimental determination == Since the α-helix is defined by its hydrogen bonds and backbone conformation, the most detailed experimental evidence for α-helical structure comes from atomic-resolution X-ray crystallography such as the example shown at right. It is clear that all the backbone carbonyl oxygens point downward (toward the C-terminus) but splay out slightly, and the H-bonds are approximately parallel to the helix axis. Protein structures from NMR spectroscopy also show helices well, with characteristic observations of nuclear Overhauser effect (NOE) couplings between atoms on adjacent helical turns. In some cases, the individual hydrogen bonds can be observed directly as a small scalar coupling in NMR. There are several lower-resolution methods for assigning general helical structure. The NMR chemical shifts (in particular of the Cα, Cβ and C′) and residual dipolar couplings are often characteristic of helices. The far-UV (170–250 nm) circular dichroism spectrum of helices is also idiosyncratic, exhibiting a pronounced double minimum at around 208 and 222 nm. Infrared spectroscopy is rarely used, since the α-helical spectrum resembles that of a random coil (although these might be discerned by, e.g., hydrogen-deuterium exchange). Finally, cryo electron microscopy is now capable of discerning individual α-helices within a protein, although their assignment to residues is still an active area of research. Long homopolymers of amino acids often form helices if soluble.
Trump's reelection in 2024 was met with consternation by Democrats. The three richest men in America attended Trump's second inauguration, and Elon Musk's formation of DOGE, as well as the enactment of Project 2025, were seen as myopic and unconstitutional, featuring policies such as reducing taxes on corporations and capital gains, instituting a flat income tax on individuals, cutting Medicare and Medicaid, reversing President Joe Biden's policies, and reducing environmental protections. After Trump won the election, Sanders released a statement blaming the Democratic Party's abandonment of "working-class people" for its defeat. In February 2025, Sanders began the "Fighting Oligarchy Tour", in which he and Ocasio-Cortez held rallies criticizing Trump's policies and economic inequality. In April 2025, Sanders criticized the administration, saying that its moving "rapidly toward oligarchy", he also called US a "pseudo-democracy". At one rally held in June 2025, Sanders reacted to news of Trump's bombing of Iranian nuclear sites by saying: "The American people are being lied to again today. We cannot allow history to repeat itself". Also in June, Sanders endorsed progressive politician and DSA member Zohran Mamdani for the 2025 New York City Democratic mayoral primary, calling him "best choice" for mayor. In September 2025, Sanders criticized Democratic Party officials for their perceived refusal to support Mamdani after his victory in the New York City mayoral primary.
== Beverages == Tea (chai) and coffee (kawa) are popular beverages and important cash crops. These can be served English-style or spiced (chai masala). Coca-Cola, Pepsi and Fanta have all made inroads in the Ugandan market and soft drinks have become very popular. Both traditional and Western beers are probably the most widely available alcoholic beverages across Uganda.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.